These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11769362)

  • 21. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.
    James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD
    Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
    Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A; Casciano R; Stern L; Svangren P
    Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Good prevention of type 2 diabetes with lipid-lowering statin therapy. Intervention studies support active treatment of risk patients].
    Nilsson PM; Attvall S; Båvenholm P
    Lakartidningen; 2004 Nov; 101(47):3798, 3801-2, 3804. PubMed ID: 15609534
    [No Abstract]   [Full Text] [Related]  

  • 29. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do people with diabetes need statins?
    White JR
    Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm--a stochastic model of exercise and dietary advice.
    Lindgren P; Fahlstadius P; Hellenius ML; Jönsson B; de Faire U
    Prev Med; 2003 Apr; 36(4):403-9. PubMed ID: 12649048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [How to finance preventive care within the buy-sell system and house-physician organizations?].
    Rosén M; Aberg G; Andersson R; Angelin B; Borgå P; Gilliam H; Holm LE; Urwitz V; Vingård E; Ostensson G
    Lakartidningen; 1992 Oct; 89(42):3455-6. PubMed ID: 1435044
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost effectiveness of coronary prevention.
    Szucs TD; März W
    Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
    [No Abstract]   [Full Text] [Related]  

  • 34. [The art of distributing resources according to needs. Criteria of the Stockholm model].
    Diderichsen F; Varde E
    Lakartidningen; 1996 Oct; 93(42):3677-8, 3680, 3683. PubMed ID: 8965530
    [No Abstract]   [Full Text] [Related]  

  • 35. PHARMAC and statins.
    Bennett W; McNee W
    N Z Med J; 1998 Nov; 111(1077):439-40. PubMed ID: 9861928
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of statins. In New Zealand, subsidy of statins is limited to particular groups of patients.
    Bennett W; McNee W; Metcalfe S; Wright JM
    BMJ; 1997 Dec; 315(7122):1616. PubMed ID: 9437288
    [No Abstract]   [Full Text] [Related]  

  • 37. [The willingness to pay for new drugs is based on ethical principles].
    Liliemark J; Lööf L; Befrits G; Back S; Sandman L
    Lakartidningen; 2016 Oct; 113():. PubMed ID: 27779723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Misleading information about statins].
    Røiri P
    Tidsskr Nor Laegeforen; 2002 Sep; 122(21):2141. PubMed ID: 12555655
    [No Abstract]   [Full Text] [Related]  

  • 39. PHARMAC at what cost?
    Moodie P; McNee W
    N Z Med J; 2000 Feb; 113(1104):64. PubMed ID: 10777230
    [No Abstract]   [Full Text] [Related]  

  • 40. A vote of no confidence in the precision of the estimated cost-effectiveness of lipid lowering.
    Cates C
    Br J Gen Pract; 2000 Nov; 50(460):917; author reply 918. PubMed ID: 11141883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.